Histotype
Brain
.png)
| Parameter | Information |
|---|---|
| Strain | C.B-17 SCID |
| Implant Type | Cells |
| Implant Location | Intracranial |
| Time to Staging | 8 days |
| Time to Evaluation Size (days) | N/A |
| Td | 2.9 days |
The above parameters are from one study. For further information on this cell line and other parameters, including different strains, vendors, implant type and location and/or standards of care, please contact us.
Tumor Line
Human
Ref #
2359
Spotlight on LN-827
Learn more about this cell line in our scientific spotlights:
Glioblastoma (GBM) patients are known to have a poor prognosis and tumor progression with high mortality and a median survival of only 12-15 months. Currently, anti-GBM therapy includes a multi-modality method involving radiotherapies and surgical removal of the tumor in combination with chemotherapy.1